Pirfenidone Solution for Inhalation (AP01) is a medication being studied for its potential to treat progressive, fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis. This medication is administered through inhalation, allowing it to directly target the lungs. The trial aims to provide patients with access to this therapy and to assess its safety for long-term use.

Interstitial Lung Diseases – Interstitial lung diseases (ILD) are a group of disorders that cause scarring of lung tissue, leading to stiffness and difficulty in breathing. The scarring, known as fibrosis, gradually worsens over time, affecting the ability of the lungs to transfer oxygen into the bloodstream. Symptoms often include a persistent dry cough and shortness of breath, especially during or after physical activity. The progression of ILD can vary significantly among individuals, with some experiencing rapid deterioration while others have a slower course. Environmental factors, such as exposure to certain toxins, and genetic predispositions can contribute to the development of these diseases.

Idiopathic Pulmonary Fibrosis – Idiopathic pulmonary fibrosis (IPF) is a specific type of interstitial lung disease characterized by the thickening and scarring of lung tissue without a known cause. This scarring makes it increasingly difficult for the lungs to function properly, leading to symptoms such as chronic dry cough and progressive shortness of breath. The disease typically affects middle-aged and older adults, and its progression can vary, with some individuals experiencing a gradual decline and others facing more rapid deterioration. The exact cause of IPF remains unknown, but it is believed to involve a combination of genetic and environmental factors. As the disease progresses, the lung tissue becomes more fibrotic, further impairing respiratory function.